Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
June 10 2020 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced that due to the health, safety and
travel concerns of stockholders and federal, state and local
government recommendations and restrictions imposed in response to
the novel coronavirus (COVID-19) pandemic, the location of its 2020
Annual Meeting of Stockholders has changed. The Annual Meeting of
Stockholders will be held virtually, by webcast, and stockholders
will not be able to attend in person. The meeting will be held on
the same date and time as originally scheduled, Tuesday, June 23,
2020 at 8 a.m. PDT.
As described in the company's proxy materials previously
distributed for the Annual Meeting, Otonomy stockholders as of the
close of business on April 24, 2020 are entitled to attend and
vote, and ask questions at the Annual Meeting.
Otonomy stockholders can access the meeting at
www.virtualshareholdermeeting.com/OTIC2020 and entering the
16-digit control number found on the proxy card, voting instruction
form, or other notices previously received by stockholders.
Stockholders may vote and ask questions during the Annual Meeting
by following the instructions available on the meeting website.
All stockholders are encouraged to vote and submit their proxies
in advance of the meeting by one of the methods described in the
proxy materials. The proxy card that was previously distributed
will not be updated to reflect the change in meeting format and may
be used to vote shares in connection with the Annual Meeting.
Stockholders who have previously sent in proxies, or voted via
telephone or by internet, do not need to take any further
action.
About Otonomy Otonomy is a
biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology. The company pioneered the
application of drug delivery technology to the ear in order to
develop products that achieve sustained drug exposure from a single
local administration. This approach is covered by a broad patent
estate and is being utilized to develop a pipeline of products
addressing important unmet medical needs including Ménière’s
disease, hearing loss, and tinnitus. For additional information,
please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne
RamseyVice President404.865.3601 cramsey@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H.
UhlManaging Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From May 2024 to Jun 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2023 to Jun 2024